Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience

Luigi Gargiuloa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Francesco Piscazzia Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Luciano Ibbaa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyCorrespondence[email protected]

Mario Valentia Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Paola Facherisb Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Chiara Peruginib Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Antonio Costanzoa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Alessandra Narcisib Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

show all

Click to increase image sizeClick to decrease image size

Disclosure statement

L. Gargiulo has received research grants from Almirall. M. Valenti has been a consultant and/or speaker for Sanofi, Leo Pharma, Eli Lilly and Boehringer Ingelhei. A. Costanzo has served as an advisory board member, consultant and has received fees and speaker’s honoraria or has participated in clinical trials for Abbvie, Almirall, Biogen, LEO Pharma, Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB-Pharma. A. Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi-Genzyme, Amgen and Boehringer Ingelheim. The other authors have nothing to disclose.

Data availability statement

Data available on request from the authors.

Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience

Information for

Open access

Opportunities

Help and information

Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience

Disclosure statement

Data availability statement

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature